Dear Readers,
Here is Michael Klug’s CV. As you know, he is also the editor and photographer for the books Sexiest at 50: PTSD PhD Marie (available here) and Art and Smart (available here). You can hear him using the Instructions for Helping to Improve the Human Condition with me as the guide here. The Instructions for Helping to Improve the Human Condition are freely available here. Printed books are also available here.
Lots of Love, Marie
Michael G. Klug, Ph.D.
Biology Instructor
Minneapolis Community & Technical College (MCTC)
1501 Hennepin Avenue
Minneapolis, MN 55403
https://www.linkedin.com/in/michael-klug-b7a7b58/
EDUCATION
Ph.D., Physiology, Indiana University School of Medicine, Indianapolis, IN, 1989-1996 (GPA 3.93 / 4.00)
B.S., Honors Biology program, with distinction, Phi Beta Kappa, Indiana University, Bloomington, Indiana, 1986-1989 (GPA 3.77 / 4.00)
Additional Graduate Level Coursework:
Successfully completed first two years of medical school (M.D.), Indiana University School of Medicine, Bloomington, IN, 1989-1991. (When I was starting back into my third year of medical school, I received a post-doc job offer in 1997 to continue my Ph.D. research and never looked back.)
Instructional Strategies for Community & Technical Colleges, Bemidji State University, Bemidji, Minnesota, 2010 (Grade: A).
Curriculum Planning and Design for Community & Technical Colleges, Bemidji State University, Bemidji, Minnesota, 2011 (Grade: A).
Assessment and Evaluation of Student Learning for Community & Technical Colleges, Bemidji State University, Bemidji, Minnesota, 2011 (Grade: A).
Philosophy of Community and Technical College Education, Minnesota State Colleges & Universities (MnSCU) Office of the Chancellor, 2012, (non-credit, required for MnSCU college faculty).
Additional Certification:
IDI (Intercultural Development Inventory), Qualified Administrator, August 2017 to present.
TEACHING EXPERIENCE
Instructor for BIOL 1100, Introduction to Biology class and laboratory sections, Minneapolis Community and Technical College (MCTC), Spring 2009.
Instructor for BIOL 1128, Human Biology laboratory, MCTC, Fall 2009, Spring 2017.
Instructor for BIOL 2200, Principles of Biology class sections, MCTC, Fall 2015.
Instructor for BIOL 2224, Human Anatomy class sections, MCTC, Fall 2009 to present.
Instructor for BIOL 2224, Human Anatomy laboratory sections, MCTC, Fall 2009 to present, (excluding parts of 2 years as Coordinator for several departments).
Instructor for BIOL 2224, Human Anatomy online laboratory sections, MCTC, Summer 2014, Fall 2014, Summer 2015.
Instructor for BIOL 2224, Human Anatomy online class sections, MCTC, Fall 2010 to present.
Instructor for BIOL 2225, Physiology online class section, MCTC, Summer 2013.
Instructor for BIOL 2225, Physiology laboratory sections, MCTC, Summer 2013, Fall 2017 to present.
Instructor for BIOL 2500, Molecular Biology class and laboratory, MCTC, Spring 2010, 2011, 2012, 2013, 2014, 2015, 2016.
Instructor for BIOT 1000, Introduction to Biosciences, MCTC, Fall 2010 to Spring 2015.
Teaching and Advising Experience Prior to Completion of Ph.D. degree:
Facilitator for the Problem Based Learning section of the Medical Physiology course, Indiana University School of Medicine, Spring 1994 and 1996.
Graduate student advisor to undergraduate Delta Chi fraternity members, 1989-1990 school year, Indiana University, Bloomington.
Associate Instructor for 2 sections of C121, undergraduate chemistry lab, Fall 1988, Indiana University, Bloomington.
COURSE DEVELOPMENT
Completely developed Molecular Biology course and laboratory (BIOL 2500). Includes a continuous, semester long laboratory project.
Completely developed online Anatomy course (BIOL 2224).
Completely developed online Anatomy laboratory (BIOL 2224).
Developed and continue to improve and optimize web and active group based enhanced learning opportunities for Anatomy courses and laboratory (BIOL 2224).
PROFESSIONAL EXPERIENCE
Summary:
Teaching while leveraging my diverse experiences in research, diagnostics, pharmaceuticals and biotechnology at the junction of life sciences, research, business development, product conception & development, and intellectual property.
Minneapolis Community and Technical College, Minneapolis, MN, USA 2009-present
Instructor for laboratories & classes in the Biology Department and Biotechnology Program.
- Equity & Inclusion, Steering Committee, Fall 2016-Present
- Equity & Inclusion, Curriculum & Pedagogy, Fall 2016-Fall 2017
- Coordinator for Astronomy, Biology, Biotechnology, Chemistry, Community Health Worker, Geology, Herbal Studies and Physics, Fall 2014-Spring 2016
- Faculty Racial Equity Committee
- Safety Committee, 2009-2013
University of Minnesota, Minneapolis, MN, USA 2006-2008
Technology Strategy Manager and Technology Transfer Liaison, Academic Health Center
Identified new revenue opportunities and de-prioritized projects with limited potential.
New technology identification, evaluation, market analyses, pre-clinical and clinical development timeline estimation and management of intellectual property (patent) filing/prosecution.
– Worked with nearly 300 researchers to screen over 1000 invention ideas.
– Patent filing and prosecution including over 200 US and foreign patents.
– Created and developed relationships between the Office for Technology Commercialization and faculty, Center Directors, Department Heads, and College Deans.
– Identified potential commercialization steps for faculty research and introduced opportunities to commercial partners, University collaborators and funding sources.
– Educated Academic Health Center (Medical, Dental, Veterinary, and Public Health Colleges) faculty on intellectual property.
Mayo Clinic, Rochester, MN, USA 2003-2006
Licensing Liaison and Contract Manager (2004-2006)
Department of Laboratory Medicine and Pathology, Mayo Collaborative Services Inc., Mayo Medical Laboratories, Legal Contract Administration, Legal Department
Identified, categorized, prioritized and actualized hundreds of projects encompassing over a thousand near-term action items. Established the business case for the creation of 6+ new positions as well as in-licensing and collaborative opportunities.
– Results included negotiation of in-licensing and collaborative agreements and creation of a cohesive team that enabled new, and protected existing, revenue streams.
Research Fellow (2003-2004)
Department of Orthopedic Research, Mayo Graduate School of Medicine
Scientific research included proteomic analyses for discovery of arthritis biomarkers.
F. Hoffmann-La Roche Ltd., Basel, Switzerland 1999-2002
Laboratory Head, Project Leader, and Genomics and Genetics Coordinator (2000-2002)
Obesity and Type II Diabetes Drug Discovery
Planned, led, motivated, organized and contributed to teams composed of professionals with diverse expertise and personalities. Results included successful implementation of key projects/collaborations and re-design or de-prioritization of unfavorable opportunities. Contributed substantively to external collaborations.
– Led and coordinated a large network of colleagues to patent potential drugs that decreased food intake and could be used to treat obesity. Overall project plans included marketing, business development, clinical trials, regulatory and other aspects of pharmaceutical discovery, development and product life cycle.
– Attended Leadership and Teamwork Course, International Institute for Management Development (IMD International), Lausanne, Switzerland.
Laboratory Head and Project Leader (1999-2000)
New Target Discovery, Congestive Heart Failure Disease Area
Planned and implemented development of new research projects and facilities.
– Developed numerous proposals for new heart failure drug projects focused on competitive improvements over existing or future therapies.
– Co-designed and supervised construction of molecular and cellular biology laboratories.
– Contributed to planning and personnel recruiting for congestive heart failure pre-clinical model laboratories.
– Contributed to plans submitted to regulatory agencies for identification and management of potential cardiovascular risks in marketed drugs.
Eli Lilly and Company, Indianapolis, IN 1997-1999
Postdoctoral Fellow
Congestive Heart Failure Drug Discovery Team, Cardiovascular Division, Lilly Research Laboratories
Established and expanded new research area including supervision of design and construction of new laboratory facilities and purchase of new equipment. Provided review of plans and data analysis for collaborating scientists in a team based environment that resulted in more efficient integration of projects.
– Designed and implemented in vitro heart cell models that optimized the drug target discovery process.
– Transferred know-how and contributed to conceptualization, planning, evaluation and ongoing interactions within team and with other Lilly Divisions, external academic and biotechnology partners.
– Recruited, trained and supervised scientists.
Indiana University School of Medicine, Bloomington; Indianapolis, IN 1989-1996
Medical and Graduate Student (M.D./Ph.D.)
Completed first 2 years of Medical School and passed first National Board Exam.
Ph.D. Coursework and Dissertation Research (1991-1996)
Breakthrough scientific research establishing that heart cells from mouse embryonic stem cells could form grafts in adult hearts.
PUBLICATIONS and PRESENTATIONS
Jensen, M., Matteis, A., Loyle, A. Contributors: Cramer, S., Felice, J., Gerrits, R., Henniger, A., Jackson, J., Klug, M., Millis, L., Parsons, A., Ross, T. Fifteen POGIL Activities for Introductory Anatomy and Physiology Courses. 2014. Wiley.
RESEARCH ARTICLES
Bergen III, H. R. Klug, M.G., Bolander, M.E., Muddiman, D. C. Informed use of protease inhibitors in biomarker discovery. Rapid Commun. Mass Spectrom. 2004. 18:1001-2.
Wang, J., Zhen L., Klug, M.G., Wood D., Wu X., Mizrahi J. Involvement of caspase 3- and 8-like proteases in ceramide-induced apoptosis of cardiomyocytes. J. Card. Fail. 2000. 6:243-9.
Sutton, J., Costa, R., Klug, M., Field, L., Xu, D., Largaispada, D.A., Fletcher C.F., Jenkins, N.A., Copeland, N.G., Klemsz, M., and Hromas, R. Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells. J. Biol. Chem. 1996. 271:23126-23133. Cited over 75 times*
Klug, M.G., Soonpaa, M.H., Koh, G.Y., and Field, L.J. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J. Clin. Invest. 1996. 98:216-214. Cited over 400 times*
Klug, M.G., Soonpaa, M.H., and Field, L.J. DNA synthesis and multinucleation in embryonic stem cell-derived cardiomyocytes. Am. J. Physiol. 1995. 269 (Heart Circ. Physiol. 38):H1913-H1921. Cited over 25 times*
Koh, G.Y., Soonpaa, M.H., Klug, M.G., Pride, H.P., Cooper, B.J., Zipes, D.P., and Field, L.J. Stable fetal cardiomyocyte grafts in the hearts of dystrophic mice and dogs. J. Clin. Invest. 1995. 96:2034-2042. Cited over 100 times*
Koh, G.Y., Kim, S.J., Klug, M.G., Park, K., Soonpaa, M.H., and Field, L.J. Targeted expression of transforming growth factor-b1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J. Clin. Invest. 1995. 95:114-121. Cited over 50 times*
Soonpaa, M.H., Koh, G.Y., Klug, M.G., and Field, L.J. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science. 1994. 264:98-101. Cited over 200 times*
Koh, G.Y., Klug, M.G., Soonpaa, M.H., and Field, L.J. Differentiation and long-term survival of C2C12 myoblast grafts in the heart. J. Clin. Invest. 1993. 92:1548-1554. Cited over 100 times*
Koh, G.Y., Soonpaa, M.H., Klug, M.G., and Field, L.J. Long-term survival of AT-1 cardiomyocyte grafts in syngeneic myocardium. Am. J. Physiol. 1993. 264 (Heart Circ. Physiol. 33):H1727-H1733. Cited over 75 times*
Lash, J.A., Helper, D.J., Klug, M.G., Nicolozakes, A.W., and Hathaway, D.R. Nucleotide and deduced amino acid sequence of cDNA’s encoding two isoforms of the 17,000 dalton light chain in bovine aortic smooth muscle. Nucleic Acids Research. 1990. 18 (23):7176. Cited over 25 times*
* Citation numbers from ISI Web of Knowledge
REVIEW ARTICLES and BOOK CHAPTERS
Soonpaa, M.H., Klug, M.G., Nakajima, H., Nakajima, H. and Field, L.J. Potential approaches for cell-mediated myocardial repair. In Wilensky, R. (ed.), Unstable coronary artery disease: Pathology, diagnosis and treatment. 1998. Kluwer Academic Press, Boston, pp. 344-354.
Soonpaa, M.H., Daud, A.I., Koh, G.Y., Klug, M.G., Kim, K.K., Wang, H., and Field, L.J. Potential Approaches for Myocardial Regeneration. Annals New York Academy of Sciences. 1995. 752:446-454.
Klug, M.G., Daud, A.I., Chandrasekhar, S., and Field, L.J., Cardiogenesis from Commitment to the Adult Phenotype. In Zipes, D.P. and Jaliffe, J. (eds.) Cardiac Electrophysiology: from cell to bedside. 2nd ed. 1995. W.B. Saunders Comp. Philadelphia, pp. 57-63.
Koh, G.Y., Soonpaa, M.H., Klug, M.G., and Field, L.J. Strategies for Myocardial Repair. Journal of Interventional Cardiology. 1995. 8:387-393.
Koh, G.Y., Klug, M.G., and Field, L.J. Atrial Natriuretic Factor and Transgenic Mice. Hypertension. 1993. 22:634-639.
EXTERNAL PRESENTATIONS and CONFERENCES (selected)
MidAmerica Herbal Symposium, Altura, MN, September 15-17, 2017.
IDI, Intercultural Development Inventory, Qualified Administrator (QA), July 27-29, 2017.
MidAmerica Herbal Symposium, Altura, MN, September 16-18, 2016.
Medtronic, Fridley, MN, March 17, 2006. Invited presentation title: “Cardiomyocytes for cardiac engraftment and pharmaceutical discovery.”
Mayo Clinic, Rochester, MN, May 19, 2003. Invited presentation title: “Cardiac and skeletal muscle cultures for drug discovery.”
Klug, M.G. (presenting author) and Kube, D.M., Swiss Physiological Society, Obesity Conference. Institute of Physiology, University of Fribourg, Switzerland, September 21, 2001. Oral presentation: “Human Genome: what’s next for metabolic diseases.”
F. Hoffman-La Roche Ltd., Basel, Switzerland, May 20, 1999. Invited presentation title: “In vitro models for elucidating the pathophysiology of congestive heart failure.”
Advanced Cell Technology Inc., Worcester, MA, April 19, 1999. Invited presentation title: “Embryonic stem cell-derived cardiomyocyte grafts in adult mice.”
Geron Corporation, Menlo Park, CA, March 24, 1999. Invited presentation title: “Embryonic stem cell-derived cardiomyocytes for intra-cardiac grafting and drug discovery.”
Gordon Conference on Cardiac Regulatory Mechanisms, New London, New Hampshire, 1998. Poster title: “Different cardiomyocyte culture conditions influence markers utilized as in vitro surrogates of cardiac dysfunction.”
Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, Pennsylvania, February 27, 1998. Invited presentation title: “Muscle cell cultures and their applications.”
Lilly Research Laboratories, Indianapolis, IN, January 16, 1997. Invited presentation title: “Embryonic stem cell-derived cardiomyocyte cultures.”
Keystone Symposium on Tissue Engineering, Taos, New Mexico, 1996. Poster title: “Purification of cardiac myocytes differentiated from embryonic stem cells for use in intracardiac grafting.”
Keystone Symposium on Tissue Engineering, Taos, New Mexico, 1994. Poster title: “DNA synthesis and multinucleation in cardiomyocytes derived from embryonic stem cells.”
Keystone Symposium on the Developmental Biology of the Cardiovascular System, Taos, New Mexico, 1993. Poster title: “Cardiomyocyte development in embryoid bodies derived from murine embryonic stem cells.”
Gordon Conference on Developmental Biology of the Cardiovascular System, Tilton, New Hampshire, 1992. Competitive application to attend meeting accepted.
Gordon Conference on Cardiac Regulatory Mechanisms, Plymouth, New Hampshire, 1992. Competitive application to attend meeting accepted.
PUBLISHED ABSTRACTS
Klug, M.G., and Field, L.J., “DNA synthesis and multinucleation in cardiomyocytes derived from embryonic stem cells.” Keystone Symposium on Tissue Transplantation, Taos, New Mexico. [J. Cellular Biochemistry 18C, page 108, 1994]
Koh, G.Y., Kim, S.-J., Klug, M.G., Park, K., Soonpaa, M.H., Wang, H., and Field, L.J. “Local, long-term delivery of recombinant secretory TGF-b1 to the myocardium by using somatic gene transfer.” Keystone Symposium [J. Cellular Biochemistry 18A, page 238, 1994]
Klug, M.G., and Field, L.J., “Cardiomyocyte development in embryoid bodies derived from murine embryonic stem cells.” Keystone Symposium on the Developmental Biology of the Cardiovascular System, Taos, New Mexico [J. Cellular Biochemistry 17D, page 199, 1993]
Daud, A.I., Katz, E., Koh, G.Y., Klug, M.G., Soonpaa, M.H., Steinhelper, M.E., and Field, L.J. “Cardiomyocyte growth in transgenic animals.” Keystone Symposium on the Developmental Biology of the Cardiovascular System, Taos, New Mexico. [J. Cellular Biochemistry 17D, page 189, 1993]
Koh, G.Y., Soonpaa, M.H., Klug, M.G., and Field, L.J. “Long-term survival of AT-1 cardiomyocyte graft in syngeneic myocardium.” Keystone Symposium on the Developmental Biology of the Cardiovascular System, Taos, New Mexico. [J. Cellular Biochemistry 17D, page 199, 1993]
PATENTS
Quinoline Derivatives (US Patents 6,787,558; 7,012, 073; 7,064,134; 7,166,589 and US Patent Applications 20030158179, 20040259858, 20060063758, 20060148794). F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Quinoline Derivatives as Neuropeptide Y Antagonists (WO03028726; Australian granted 2002342735, Korean granted 1020047004591, New Zealand granted 531517), F. Hoffmann-La Roche Ltd., Basel, Switzerland.
3 thoughts on “Michael Klug’s Curriculum Vitae”